Table I.
Univariate analyses of association between BRAF-V600E mutation status and clinicopathological parameters in <55-age group.
| BRAF-V600E | |||||
|---|---|---|---|---|---|
| Patients' parameters | Total | Mutation | Wild-type | Odds ratio (95% CI) | P-value |
| Age, years (mean ± standard deviation) | 38±10 | 39±10 | 37±10 | NA | 0.083 |
| Sex, n | |||||
| Female | 249 | 128 | 121 | 1 | 0.910 |
| Male | 69 | 36 | 33 | 1.031 (0.605–1.759) | |
| Ethnicity category, n | |||||
| Caucasian | 207 | 116 | 91 | 1 | 0.742 |
| Asian | 38 | 20 | 18 | 0.872 (0.436–1.744) | |
| Black | 15 | 7 | 8 | 0.686 (0.240–1.963) | |
| Tumor size, cm (mean ± standard deviation) | 1.7±0.8 | 1.6±0.9 | 1.7±0.8 | NA | <0.001a |
| Tumor foci, n | |||||
| Unifocality | 285 | 36 | 249 | 1 | 0.036a |
| Multifocality | 33 | 0 | 33 | 1.133 (1.085–1.182) | |
| Lymphocytic thyroiditis, n | |||||
| No | 240 | 119 | 120 | 1 | 0.099 |
| Yes | 45 | 29 | 17 | 1.720 (0.898–3.296) | |
| Histology, n | |||||
| CPTC | 237 | 142 | 95 | 1 | <0.001a |
| FVPTC | 63 | 9 | 54 | 0.112 (0.053–0.237) | |
| TCPTC | 18 | 13 | 5 | 1.739 (0.600–5.039) | |
| Lymph nodes positivity, n (>5) | |||||
| No | 190 | 102 | 88 | 1 | 0.618 |
| Yes | 60 | 30 | 30 | 0.863 (0.483–1.542) | |
| ETE, n (gross) | |||||
| No | 307 | 160 | 147 | 1 | 1.000b |
| Yes | 2 | 1 | 1 | 0.919 (0.057–14.822) | |
| Residual tumor, n | |||||
| No | 253 | 137 | 116 | 1 | 0.098 |
| Yes | 29 | 11 | 18 | 0.517 (0.235–1.140) | |
| RAI therapy, n | |||||
| No | 123 | 62 | 61 | 1 | 0.771 |
| Yes | 163 | 85 | 78 | 1.072 (0.671–1.713) | |
| RAI dose, mCi (mean ± standard deviation) | 121±59 | 120±50 | 122±68 | NA | <0.001a |
| Recurrence follow-up, months | 21 (14–44) | 26 (16–50) | 18 (12–39) | NA | 0.001a |
| Recurrence, n | |||||
| No | 278 | 143 | 135 | 1 | 0.865 |
| Yes | 13 | 7 | 6 | 1.101 (0.361–3.360) | |
| Mortality follow-up, months | 21 (13–44) | 25 (15-51.25) | 18 (12-39.5) | NA | 0.001a |
| Mortality, n | |||||
| No | 318 | 164 | 154 | 1 | NA |
| Yes | 0 | 0 | 0 | NA | |
| Recurrence risk stage, n | |||||
| Low | 108 | 26 | 82 | 1 | <0.001a |
| Intermediate | 163 | 124 | 39 | 10.028 (5.675–17.719) | |
| High | 33 | 13 | 20 | 2.050 (0.898–4.682) | |
| T stage, nc | |||||
| 1 | 221 | 114 | 107 | 1 | 0.981 |
| 2 | 69 | 36 | 33 | 1.024 (0.596–1.759) | |
| 3 | 28 | 14 | 14 | 0.939 (0.428–2.061) | |
| 4 | 0 | NA | NA | NA | |
| N stage nc | |||||
| 0 | 133 | 62 | 71 | 1 | 0.105 |
| 1a | 68 | 42 | 26 | 1.850 (1.019–3.357) | |
| 1b | 45 | 21 | 24 | 1.002 (0.509–1.973) | |
| M stage, nc | |||||
| 0 | 178 | 96 | 82 | 1 | 1.000b |
| 1 | 4 | 2 | 2 | 0.854 (0.118–6.199) | |
| AJCC stage, nc | |||||
| I | 314 | 162 | 152 | 1 | 1.000b |
| II | 4 | 2 | 2 | 0.938 (0.131–6.744) | |
Recurrence/mortality follow-up (months) were described by median or interquartile range. Low recurrence risk, intrathyroidal differentiated thyroid cancer and ≤5 LN micrometastases (<0.2 cm); intermediate recurrence risk, aggressive histology, minor ETE, vascular invasion, or >5 involved lymph nodes (0.2–3 cm); high recurrence risk, gross ETE, incomplete tumor resection, distant metastases or lymph node >3 cm. CI, confidence intervals; CPTC, conventional papillary thyroid cancer; FVPTC, follicular variant papillary thyroid cancer; TCPTC, tall cell variant papillary thyroid cancer; ETE, extrathyroidal extension; RAI, radioactive iodine; T, tumor size; N, lymph node; M, metastasis; AJCC staging, 8th edition American Joint Committee on Cancer staging; aP<0.05; bFisher's exact test; c(11).